Food News and Research

RSS

FDA approves Combunox tablets for the short-term treatment of acute, moderate to severe pain

Forest Laboratories have announced that Combunox (Oxycodone HCl and Ibuprofen) Tablets (CII), the first and only fixed-dose combination of the opioid oxycodone HCl (5 mg) and the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen (400 mg), was approved by the U.S. Food and Drug Administration (FDA) for the short-term management of acute, moderate to severe pain.

29 Nov 2004

Testosterone patches for women with low sex drive

The Food and Drug Administration (FDA) has granted a fast track review of testosterone patches for women with low sex drive, despite concerns about insufficient data and potentially misleading marketing by their manufacturer Proctor & Gamble, claim two articles in this week's BMJ.

29 Nov 2004

FDA approves Remodulin for the treatment of pulmonary arterial hypertension

United Therapeutics Corporation announced today that the U.S. Food and Drug Administration (FDA) has issued an approval letter for the intravenous use of Remodulin based on data establishing its bioequivalence with the previously approved subcutaneous administration of Remodulin.

24 Nov 2004

European regulators should avoid excessive legislation when trying to tackle obesity

European regulators should avoid excessive legislation when trying to tackle the increasing problem of overweight groups in their population, according to a new study by Austrian researchers published today by the Brussels think-tank the European Enterprise Institute (EEI).

24 Nov 2004

Cord blood registry sees FDA regulation as good for consumers and industry

Beginning in May 2005, cord blood banks must meet new federal safety standards mandated by the Food and Drug Administration (FDA).

24 Nov 2004

Parents are not happy about television food advertising directed at their children

Responses from parents of school aged children found that while parents were sceptical about claims made by food advertising, they considered it to exert a strong influence on their children.

24 Nov 2004

New allergen working group in New Zealand

Food Industry and Consumer representatives and regulators have met in Auckland and Christchurch to set up an Allergen Working Group in New Zealand.

24 Nov 2004

MedImmune and Medarex have announced a collaboration to develop antibodies

MedImmune and Medarex have announced a collaboration to develop antibodies targeting interferon-alpha and the type I interferon receptor 1.

24 Nov 2004

FDA approval of Tysabri, for the treatment of multiple sclerosis

Biogen and Elan Corporation have announced that the U.S. Food and Drug Administration (FDA) has approved Tysabri (natalizumab), as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses.

24 Nov 2004

Chylomicrons may be as dangerous or more dangerous than low-density lipoprotein (LDL) cholesterol

You may not yet have heard of chylomicrons, but a nutritional scientist at the University of Alberta believes you will soon--especially if you care about preventing a stroke or heart attack.

24 Nov 2004

CDC admits obesity stats flawed - pharmaceutical and weight loss industry at fault

A Wall Street Journal bombshell report that the U.S. Centers for Disease Control and Prevention (CDC) has admitted to serious statistical errors in calculating that obesity kills 400,000 Americans each year is only the tip of the iceberg of gross exaggerations and miscalculations, according to The Center for Consumer Freedom (CCF).

24 Nov 2004

Positive results of study with human lactoferrin

Pharming Group N.V. announced today the positive results from a key study with recombinant human lactoferrin (rhLF). The Company will use these results for Generally Regarded as Safe (GRAS) registration of rhLF for nutritional applications.

24 Nov 2004

FDA incapable of protecting America against another Vioxx

The Food and Drug Administration (FDA) tried to discredit one of its own experts after he told a US Senate hearing that the FDA had failed to protect the public over rofecoxib (Vioxx), according to two articles published online by the British Medical Journal.

24 Nov 2004

FDA approves Vesicare (solifenacin succinate) for the treatment of overactive bladder

Vesicare (solifenacin succinate) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of overactive bladder (OAB) with symptoms of urgency, frequency, and urge incontinence.

23 Nov 2004

On average, American households waste 14 percent of their food purchases

As they sit down to their Thanksgiving Day dinner, many Americans will marvel at the cornucopia of food at their table. What many don't think about is how much food is wasted, not just on Thursday, but every day, from the beginning of the harvest to the scraps tossed into the garbage.

23 Nov 2004

Concealment of drugs in food and beverages in nursing homes is common

The practice of concealing drugs in patients' food and drinks is common in nursing homes, claim researchers from Norway in a study published on bmj.com today.

23 Nov 2004

Patients taking the lipid-lowering medications have a relatively low risk of developing rhabdomyolysis

Patients taking the lipid-lowering medications atorvastatin, pravastatin, and simvastatin to reduce cholesterol levels, have a relatively low risk of developing rhabdomyolysis, (a disorder that causes the breakdown of muscle), according to a new study in the December 1 issue of JAMA.

23 Nov 2004

Canadian measures to enhance BSE surveillance

Statement by Andy Mitchell, Minister of Agriculture and Agri-Food and Minister responsible for the Canadian Food Inspection Agency.

20 Nov 2004

FDA approves Tarceva (erlotinib)

OSI Pharmaceuticals and Genentech have announced that the U.S. Food and Drug Administration (FDA) has approved, after priority review, Tarceva (erlotinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.

20 Nov 2004

Transcranial Magnetic Stimulation to treat major depression

Psychiatrists at Rush University Medical Center are testing a noninvasive technique that uses repeated short bursts of magnetic energy to stimulate nerve cells in the brain to treat major depression.

20 Nov 2004